Development contract to design hot and cold contrast therapy

The product will offer a simple, safe and effective solution to providing hot and cold contrast therapy, with the added benefit of adjustable compression to the treatment area. This is achieved without complicated heating or cooling systems, and with no need for air compressors.

Morgan IAT has been contracted by the inventor, Thesis to refine the design and development of the CombiPod from patented prototype stage up to CE mark approval and commercialisation. Once the product is approved for sale in the UK, and following trials and feedback, Morgan IAT will begin manufacturing at its factory premises in Hampshire.

Nigel Clark, CEO at Morgan IAT said: “We have done a number of these Technical Files for CE Mark and FDA approvals, so we understand exactly what needs to go into the files and which test houses to approach.”

Ana Mardell, Managing Director of Thesis said: “This is a very exciting project for Thesis Technology and we are delighted to be working with Morgan IAT to help bring our concept to market."